Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?
- PMID:36366946
- PMCID: PMC9878177
- DOI: 10.1111/eci.13906
Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has entered its endemic phase and we observe significantly declining infection fatality rates due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On this background, it is crucial but challenging to define current and future vaccine policy in a population with a high immunity against SARS-CoV-2 conferred by previous infections and/or vaccinations. Vaccine policy must consider the magnitude of the risks conferred by new infection(s) with current and evolving SARS-CoV-2 variants, how these risks vary in different groups of individuals, how to balance these risks against the apparently small, but existent, risks of harms of vaccination, and the cost-benefit of different options. More evidence from randomized controlled trials and continuously accumulating national health data is required to inform shared decision-making with people who consider vaccination options. Vaccine policy makers should cautiously weight what vaccination schedules are needed, and refrain from urging frequent vaccine boosters unless supported by sufficient evidence.
Keywords: COVID-19; SARS-CoV-2; booster; epidemiology; risk; vaccine policy.
© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Conflict of interest statement
The authors report no conflicts of interest.
Similar articles
- Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Lye DC, Tan KB.Tan CY, et al.Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.Lancet Infect Dis. 2023.PMID:36924786Free PMC article.
- Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM.Tsang NNY, et al.Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.Lancet Infect Dis. 2023.PMID:36521506Free PMC article.
- Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective.Priyanka, Choudhary OP, Singh I.Priyanka, et al.Hum Vaccin Immunother. 2022 Dec 31;18(1):2020572. doi: 10.1080/21645515.2021.2020572. Epub 2022 Jan 13.Hum Vaccin Immunother. 2022.PMID:35026127Free PMC article.
- Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Chaudhary JK, Yadav R, Chaudhary PK, Maurya A, Kant N, Rugaie OA, Haokip HR, Yadav D, Roshan R, Prasad R, Chatrath A, Singh D, Jain N, Dhamija P.Chaudhary JK, et al.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.Cells. 2021.PMID:34831172Free PMC article.Review.
- Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Sane Schepisi M.Sane Schepisi M.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081.Epidemiol Prev. 2023.PMID:38314543Review.English.
Cited by
- A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C.Chatterjee S, et al.Viruses. 2023 Jan 5;15(1):167. doi: 10.3390/v15010167.Viruses. 2023.PMID:36680207Free PMC article.Review.
- SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.Iketani S, Ho DD.Iketani S, et al.Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.Cell Chem Biol. 2024.PMID:38640902Free PMC article.Review.
- Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study.Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Al Thani AA, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ.Altarawneh HN, et al.EBioMedicine. 2023 Sep;95:104734. doi: 10.1016/j.ebiom.2023.104734. Epub 2023 Jul 27.EBioMedicine. 2023.PMID:37515986Free PMC article.
- Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.Chalupka A, Richter L, Chakeri A, El-Khatib Z, Theiler-Schwetz V, Trummer C, Krause R, Willeit P, Benka B, Ioannidis JPA, Pilz S.Chalupka A, et al.Eur J Clin Invest. 2024 Mar;54(3):e14136. doi: 10.1111/eci.14136. Epub 2023 Nov 30.Eur J Clin Invest. 2024.PMID:38032853Free PMC article.
- Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic.Kapten K, Orczyk K, Smolewska E.Kapten K, et al.Arch Immunol Ther Exp (Warsz). 2023 Feb 21;71(1):7. doi: 10.1007/s00005-023-00673-0.Arch Immunol Ther Exp (Warsz). 2023.PMID:36810662Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous